Specifically, retrospective analyses from the Breast Cancer Linkage Consortium showed a relative risk (RR) of PCa in male BRCA2 and BRCA1 mutation carriers of 4.65 (95% confidence interval (CI): 3.48–6.22) and 1.07 (95% CI 0.75–1.54) respectively, the latter being similar to the general population. The gene discussed is BRCA2; the disease is breast cancer.